OOIR: Observatory of International Research

Papers

(The H4-Index of Alimentary Pharmacology & Therapeutics is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease	117
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world	109
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging	109
Systematic review: the global incidence of faecal microbiota transplantation‐related adverse events from 2000 to 2020	109
Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma	81
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment	81
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis	58
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH	57
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases	55
Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations	55
Systematic review with meta‐analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma	53
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents	52
Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders	51
Systematic review with meta‐analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease	50
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study	50
Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality	49
Umbrella review of 42 systematic reviews with meta‐analyses: the safety of proton pump inhibitors	49
Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Austral	48
Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study	47
Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments	47
Review article: emerging drug therapies in inflammatory bowel disease	46
Alcohol‐associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics	45
Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom	45
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure	44
Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis	44

Impact of Rome IV irritable bowel syndrome on work and activities of daily living	44
Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis	44
Systematic review with meta‐analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations	41
Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B	41
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study	41
Novel impedance‐pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro‐oesophageal reflux disease according to Lyon Consensus	41
Meta‐analysis: global prevalence, trend and forecasting of non‐alcoholic fatty liver disease in children and adolescents, 2000–2021	39
Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease	39
Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis	39
Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease	39
Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study	36
Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease	36
Review article: obesity and colorectal cancer	36
Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study	36